نتایج جستجو برای: temozolomide

تعداد نتایج: 4766  

2010
Gregor Dresemann

Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and the most frequent primary tumor of the central nervous system. The median survival of newly diagnosed GBM patients was between 9 to 12 months prior to treatment with temozolomide being introduced. Primary resection that is as complete as possible is recommended for malignant glioma. Conventional fractionated ...

2012
Leon D. Ortiz Luis V. Syro Bernd W. Scheithauer Fabio Rotondo Humberto Uribe Camilo E. Fadul Eva Horvath Kalman Kovacs

Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the avai...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Melissa L Fishel Ying He Martin L Smith Mark R Kelley

PURPOSE To improve the treatment of women with ovarian cancer, we are investigating the modulation of a prominent DNA-damaging agent, temozolomide, by manipulating the DNA base excision repair (BER) pathway via BER inhibitor, methoxyamine, and overexpression of N-methylpurine DNA glycosylase (MPG). EXPERIMENTAL DESIGN Enhancement of temozolomide via methoxyamine and MPG overexpression was ana...

2014
So Hyun Bae Min-Jung Park Min Mi Lee Tae Min Kim Se-Hoon Lee Sung Yun Cho Young-Hoon Kim Yu Jung Kim Chul-Kee Park Chae-Yong Kim

This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed the medical records of 300 malignant glioma patients treated with temozolomide in two medical institutions in Korea between 2004 and 2010. Two hundred nine patients experienced a total of 618 toxicities during temozolomide the...

Journal: :Brain : a journal of neurology 2015
Hui Luo Zhengxin Chen Shuai Wang Rui Zhang Wenjin Qiu Lin Zhao Chenghao Peng Ran Xu Wanghao Chen Hong-Wei Wang Yuanyuan Chen Jingmin Yang Xiaotian Zhang Shuyu Zhang Dan Chen Wenting Wu Chunsheng Zhao Gang Cheng Tao Jiang Daru Lu Yongping You Ning Liu Huibo Wang

Resistance to temozolomide poses a major clinical challenge in glioblastoma multiforme treatment, and the mechanisms underlying the development of temozolomide resistance remain poorly understood. Enhanced DNA repair and mutagenesis can allow tumour cells to survive, contributing to resistance and tumour recurrence. Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolom...

Journal: :Molecular cancer therapeutics 2008
Mingzhong Zheng Dora Bocangel Rajagopal Ramesh Suhendan Ekmekcioglu Nancy Poindexter Elizabeth A Grimm Sunil Chada

Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy. Temozolomide, a promising new derivative of dacarbazine, is currently being tested for treatment of metastatic melanoma. Resistance to alkylating agents such as temozolomide correlates with increased expression of DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Interleukin-24 (IL...

F. Mollaamin F. Najafi H. Aghaie L. Saedi

In this work, we have studied the solvent effects on values of Gibbs free energy, enthalpy. entropy and dipolemoment in spread of solvents around anticancer thug of temreolomide that is an alighting agent. For thispurpose, the quantum mechanic calculations bawd on Hanrertnick theory at the STO-36/3-2Ith levels havebeen done. Moreover, we have compared resulted thermodynamic values in gas phase ...

Journal: :JAMA 2017
Roger Stupp Andrew Kanner David M. Steinberg Benoit Lhermitte Manmeet S. Ahluwalia Francesco Di Meco Frank Lieberman David D. Tran Eilon D. Kirson Chae-Yong Kim

Importance Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor. Objective To investigate whether TTFields improves progression-free and overall survival of patients with glioblastoma, a fatal disease that commonly recurs at the initial t...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Ravi K Amaravadi Lynn M Schuchter David F McDermott Amy Kramer Lydia Giles Kristi Gramlich Mary Carberry Andrea B Troxel Richard Letrero Katherine L Nathanson Michael B Atkins Peter J O'Dwyer Keith T Flaherty

PURPOSE: The combination of the oral alkylating agent temozolomide and the oral multikinase inhibitor sorafenib was evaluated in advanced melanoma patients. EXPERIMENTAL DESIGN: Patients with metastatic melanoma (n = 167) were treated on four arms. All patients received sorafenib at 400 mg p.o. twice daily without interruption. Patients without brain metastases or prior temozolomide were random...

Journal: :JCI insight 2017
Nathaniel H Boyd Kiera Walker Joshua Fried James R Hackney Paul C McDonald Gloria A Benavides Raffaella Spina Alessandra Audia Sarah E Scott Catherine J Libby Anh Nhat Tran Mark O Bevensee Corinne Griguer Susan Nozell G Yancey Gillespie Burt Nabors Krishna P Bhat Eli E Bar Victor Darley-Usmar Bo Xu Emily Gordon Sara J Cooper Shoukat Dedhar Anita B Hjelmeland

Tumor microenvironments can promote stem cell maintenance, tumor growth, and therapeutic resistance, findings linked by the tumor-initiating cell hypothesis. Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs). Temozolomide efficacy may be increased by targeting carbon...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید